900 Ridgebury Rd.
P.O. Box 368
Ridgefield , CT 06877
USA
Related Content
October 7, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for ...
October 07, 2021
June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...
June 21, 2021
October 11, 2018 — Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance ...
October 11, 2018
June 27, 2018 — Results from a 902-person, five-country survey of people living with atrial fibrillation (AF) reinforce ...
June 27, 2018
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs ...
May 31, 2017
March 29, 2017 — Uninterrupted treatment with dabigatran (Pradaxa), a non-vitamin K, novel antagonist oral anticoagulant ...
March 29, 2017
September 1, 2016 — First outcome results from the GLORIA-AF Registry show that treatment with Pradaxa (dabigatran ...
September 01, 2016FDA Approves Dabigatran for Prophylaxis of DVT, Pulmonary Embolism and After Hip Replacement Surgery
November 24, 2015 – The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals’ ...
November 24, 2015
November 11, 2015 — Brigham and Women’s Hospital in Boston and Boehringer Ingelheim announced the results of a new ...
November 11, 2015
October 19, 2015 — The U.S. Food and Drug Administration (FDA) granted accelerated approval to Praxbind (idarucizumab) ...
October 19, 2015